Johnson & Johnson (J&J) is a global healthcare company that researches, develops, manufactures, and sells a wide range of products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech. J&J's primary focus is on products related to human health and well-being.

Innovative Medicine focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

MedTech offers a broad portfolio of products used in interventional solutions, orthopedics, surgery, and vision. These products are distributed to wholesalers, hospitals, and retailers and are used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics.

J&J operates in virtually all countries of the world. The company's strategy focuses on attracting, developing, and empowering talent while fostering a culture of diversity, equity, and inclusion.

• Employees: 134,400 (as of December 31, 2023)
• Geographic Footprint: Operates in virtually all countries
• Number of Manufacturing Facilities: 61
• Headquarters: New Brunswick, New Jersey
• Founded: 1887
• Revenue: $85.2 billion (FY2023)
• Market Capitalization: $430 billion (as of Q2 2023)
• Key Subsidiaries/Brands: Janssen, DePuy Synthes, Ethicon, Biosense Webster, Cerenovus, Mentor, Acclarent, Johnson & Johnson Vision, Abiomed, etc.

• CEO and Chairman: Joaquin Duato
• CFO: Joseph J. Wolk
• Other Key Executives: Vanessa Broadhurst (Executive VP, Global Corporate Affairs), Peter M. Fasolo, Ph.D. (Executive VP, Chief Human Resources Officer), Elizabeth Forminard (Executive VP, General Counsel), William N. Hait, M.D., Ph. D. (Executive VP, Chief External Innovation and Medical Officer), John C. Reed, M.D., Ph.D. (Executive VP, Innovative Medicine, R&D), Tim Schmid (Executive VP, Worldwide Chairman, MedTech), James Swanson (Executive VP, Chief Information Officer), Jennifer L. Taubert (Executive VP, Worldwide Chairman, Innovative Medicine), Kathryn E. Wengel (Executive VP, Chief Technical Operations & Risk Officer)

• Annual Revenue: $85.2 Billion (FY2023)
• Net Income: $35.2 Billion (FY2023)
• Market Cap: $430 billion (as of Q2 2023)
• Total Assets: $167.6 billion (FY2023)
• Number of Employees: 134,400 (as of December 31, 2023)
• Key Financial Highlights (FY2023): Worldwide sales increased 6.5%; U.S. sales increased 10.6%; International sales increased 1.9%

Innovative Medicine:

• Pharmaceutical products focused on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

MedTech:

• Medical devices and technologies used in interventional solutions, orthopedics, surgery, and vision.

• Innovative Medicine: $54.8 billion in revenue (FY2023)
• MedTech: $30.4 billion in revenue (FY2023)

J&J's business strategy centers around its credo, which emphasizes responsibility to patients, consumers, customers, healthcare professionals, employees, communities, and shareholders. The company's human capital management strategy focuses on attracting, developing, and empowering talent. J&J fosters a culture of diversity, equity, and inclusion and invests heavily in research and development to drive innovation and growth.

J&J's strategic priorities include:

• Blending heart, science, and ingenuity to impact health for humanity.
• Preventing, treating, and curing complex diseases.
• Developing smarter and less invasive treatments.
• Creating personalized solutions.

J&J operates in the global healthcare industry, competing with companies of all sizes on factors such as cost-effectiveness, technological innovation, intellectual property rights, product performance, pricing, and availability. The company faces increasing competition from generic and biosimilar products. J&J operates in a highly regulated industry and is subject to pricing pressures from government healthcare programs and private insurers.

• Competition in product markets and pricing pressures.
• Interruptions and delays in manufacturing operations and reliance on third-party manufacturers and suppliers.
• Counterfeit products and diversion of authentic products.
• Global health crises and other outbreaks.
• Healthcare reforms and increasing pricing pressures.
• Government regulation and legal proceedings.
• Challenges to intellectual property rights.
• Challenges and delays in product development, regulatory approval, and commercialization.
• Financial and economic market risks associated with international operations.
• Recruiting and retaining talent and maintaining a diverse workforce.
• Climate change and related regulations.
• Information security incidents and cybersecurity breaches.
• Breaches of privacy laws and unauthorized access to personal data.
• Inability to achieve anticipated strategic and financial benefits from the Kenvue separation.
• Potential tax liability related to the Kenvue separation.